Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b

Table 2 Proteins found to be significantly different between the sustained responders and non-responders before initiating peginterferon-Interferon alfa-2b treatment

Spot	Protein	NCBI ID	MS score	%cov	pI	MW	Relative intensity (mean ± SE)		SVR/NR	P value
							SVR	NR
Protease inhibitor
97	Chain A, alpha-1-antitrypsin	Gi|157831596	399	64	5.37	44.28	0.2764 ± 0.0327	0.4275 ± 0.0609	2.34	0.038
Transport protein and protein binding
33	Albumin, isoform	Gi|119626065	539	38	6.96	61.12	0.0330 ± 0.0121	0.0764 ± 0.0144	2.31	0.033
146	Albumin	Gi|332356380	243	41	5.73	68.48	0.0602 ± 0.0182	0.1516 ± 0.0333	2.52	0.024
Acute phase protein
309	Alpha-2-HS-glycoprotein	Gi|112910	507	40	5.43	40.09	0.7165 ± 0.0238	0.4782 ± 0.0851	0.67	0.012
Immunity protection
59	Chain C, human complement C3c	Gi|78101271	513	70	4.79	40.20	0.3969 ± 0.0391	0.2675 ± 0.0403	0.67	0.034
145	CD5 antigen-like precursor	Gi|5174411	443	67	5.28	39.60	0.1086 ± 0.0192	0.1903 ± 0.0197	1.75	0.009
Lipid metabolism
17	Chain A, crystal structure of lipid-free human apoliprotein A-I	Gi|90108664	1347	78	5.27	28.06	9.4993 ± 0.5044	6.0364 ± 1.0047	0.64	0.005

SVR: Sustained virological response; NR: Non-responder.